Your session is about to expire
← Back to Search
STING Agonist
ADU-S100 for Head and Neck Squamous Cell Carcinoma
Phase 2
Waitlist Available
Research Sponsored by Chinook Therapeutics, Inc. (formerly Aduro)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 25 months
Awards & highlights
Summary
ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.
Eligible Conditions
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancers
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 25 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 25 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evaluation of Clinical Activity by the Objective Response Rate (ORR; Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Trial Design
1Treatment groups
Experimental Treatment
Group I: ADU-S100 and pembrolizumabExperimental Treatment1 Intervention
All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
Find a Location
Who is running the clinical trial?
Chinook Therapeutics, Inc. (formerly Aduro)Lead Sponsor
1 Previous Clinical Trials
47 Total Patients Enrolled
Chinook Therapeutics, Inc.Lead Sponsor
8 Previous Clinical Trials
1,016 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger